DK1157005T3 - 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister - Google Patents

3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister

Info

Publication number
DK1157005T3
DK1157005T3 DK00909174T DK00909174T DK1157005T3 DK 1157005 T3 DK1157005 T3 DK 1157005T3 DK 00909174 T DK00909174 T DK 00909174T DK 00909174 T DK00909174 T DK 00909174T DK 1157005 T3 DK1157005 T3 DK 1157005T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
phenylpyridine derivatives
phenylpyridine
derivatives
antagonists
Prior art date
Application number
DK00909174T
Other languages
Danish (da)
English (en)
Inventor
Michael Boes
Guido Galley
Walter Hunkeler
Patrick Schnider
Heinz Stadler
Thierry Godel
Torsten Hoffmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1157005T3 publication Critical patent/DK1157005T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK00909174T 1999-02-24 2000-02-15 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister DK1157005T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99103503 1999-02-24
EP00909174A EP1157005B1 (fr) 1999-02-24 2000-02-15 Derives de 3-phenylpyridine et utilisation de ces derniers comme antagonistes de recepteur nk-1
PCT/EP2000/001223 WO2000050401A1 (fr) 1999-02-24 2000-02-15 Derives de 3-phenylpyridine et utilisation de ces derniers comme antagonistes de recepteur nk-1

Publications (1)

Publication Number Publication Date
DK1157005T3 true DK1157005T3 (da) 2005-02-14

Family

ID=8237624

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00909174T DK1157005T3 (da) 1999-02-24 2000-02-15 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister

Country Status (33)

Country Link
US (1) US6225316B1 (fr)
EP (1) EP1157005B1 (fr)
JP (1) JP4068305B2 (fr)
KR (1) KR100437587B1 (fr)
CN (1) CN1134417C (fr)
AR (1) AR029616A1 (fr)
AT (1) ATE280158T1 (fr)
AU (1) AU772446B2 (fr)
BR (1) BR0008494A (fr)
CA (1) CA2364662C (fr)
CO (1) CO5140087A1 (fr)
CZ (1) CZ20013047A3 (fr)
DE (1) DE60015089T2 (fr)
DK (1) DK1157005T3 (fr)
ES (1) ES2230070T3 (fr)
GC (1) GC0000183A (fr)
HK (1) HK1044942B (fr)
HR (1) HRP20010604A2 (fr)
HU (1) HUP0200139A3 (fr)
IL (2) IL144851A0 (fr)
JO (1) JO2254B1 (fr)
MA (1) MA26773A1 (fr)
MY (1) MY122630A (fr)
NO (1) NO320099B1 (fr)
NZ (1) NZ513370A (fr)
PL (1) PL350428A1 (fr)
PT (1) PT1157005E (fr)
RU (1) RU2236402C2 (fr)
SI (1) SI1157005T1 (fr)
TR (1) TR200102489T2 (fr)
WO (1) WO2000050401A1 (fr)
YU (1) YU59901A (fr)
ZA (1) ZA200106371B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928222D0 (en) * 1999-11-30 2000-01-26 Univ Sheffield Chiral catalysts for asymmetric acylation and related transformations
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
MXPA03000366A (es) * 2000-07-14 2003-05-27 Hoffmann La Roche N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina.
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
CA2448729A1 (fr) * 2000-11-20 2002-05-23 Biovitrum Ab Composes heterocycliques substitues par des groupes piperazinyle et piperidyle
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US7176322B2 (en) * 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
WO2004026823A1 (fr) * 2002-09-20 2004-04-01 Pfizer Products Inc. Ligands d'amides et de sulfonamides du recepteur oestrogenique
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
EP1945632B1 (fr) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Modulateurs hétérocycliques de transporteurs à cassette liant l' atp
EP1954678B1 (fr) * 2005-11-30 2012-03-21 Abbott Products GmbH Nouveaux antagonistes de nk1 et de nk2
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
PE20090277A1 (es) * 2007-04-24 2009-04-06 Takeda Pharmaceutical Derivados de piperidina como antagonistas de taquiquininas
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2639224B1 (fr) 2007-12-07 2016-08-24 Vertex Pharmaceuticals Incorporated Procédés de fabrication d'acides cycloalkylcarboxamido-pyridine benzoïques
SI2225230T1 (sl) 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
KR100943878B1 (ko) * 2008-07-11 2010-02-24 오토스테크 주식회사 디지털방식 눈부심 방지 장치 및 그 제어 방법
MX2011004551A (es) * 2008-10-30 2011-05-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida.
US8519134B2 (en) 2009-11-17 2013-08-27 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
US8410107B2 (en) * 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
WO2013112804A1 (fr) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations d'acide 3-(6-(1-(2,2-difluorobenzo [d] [1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-méthylpyridin-2-yl) benzoïque
CA2930008A1 (fr) 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Derive de carboxymethylpiperidine
JP6963896B2 (ja) 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Cftr媒介性疾患の処置のための医薬組成物を調製する方法
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
PT3221692T (pt) 2014-11-18 2021-09-10 Vertex Pharma Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
CN115531553A (zh) 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
EP4146628A1 (fr) 2020-05-06 2023-03-15 Bayer Aktiengesellschaft Pyridine (thio)amides en tant que composés fongicides
BR112022024405A2 (pt) 2020-06-04 2023-01-31 Bayer Ag Heterociclil piridinas como novos fungicidas
WO2023099445A1 (fr) 2021-11-30 2023-06-08 Bayer Aktiengesellschaft Bis(hétéro)aryl thioéther oxadiazines utilisées en tant que composés fongicides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4174209A (en) * 1978-06-19 1979-11-13 Eli Lilly And Company Herbicidal 1-alkyl-3-phenylpyridinium salts
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
CA2080249C (fr) * 1990-05-31 1996-11-19 Dennis M. Godek Obtention de piperidines a substituant
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
IL112134A (en) 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
EP0733632B1 (fr) * 1995-03-24 2003-06-04 Takeda Chemical Industries, Ltd. Composés cycliques, leur préparation et leur utilisation comme antagonistes de récepteurs de la tachykinine
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders

Also Published As

Publication number Publication date
HUP0200139A2 (en) 2002-06-29
ES2230070T3 (es) 2005-05-01
KR100437587B1 (ko) 2004-06-30
CN1134417C (zh) 2004-01-14
HUP0200139A3 (en) 2003-01-28
HK1044942A1 (en) 2002-11-08
TR200102489T2 (tr) 2002-04-22
CA2364662C (fr) 2009-10-20
CZ20013047A3 (cs) 2002-02-13
CA2364662A1 (fr) 2000-08-31
PT1157005E (pt) 2005-02-28
NO20014098L (no) 2001-08-23
AR029616A1 (es) 2003-07-10
MA26773A1 (fr) 2004-12-20
NO20014098D0 (no) 2001-08-23
IL144851A0 (en) 2002-06-30
PL350428A1 (en) 2002-12-16
AU772446B2 (en) 2004-04-29
DE60015089D1 (de) 2004-11-25
ATE280158T1 (de) 2004-11-15
HRP20010604A2 (en) 2002-08-31
IL144851A (en) 2006-08-20
EP1157005B1 (fr) 2004-10-20
MY122630A (en) 2006-04-29
NZ513370A (en) 2004-02-27
US6225316B1 (en) 2001-05-01
ZA200106371B (en) 2002-11-04
BR0008494A (pt) 2002-02-05
CO5140087A1 (es) 2002-03-22
GC0000183A (en) 2006-03-29
JP4068305B2 (ja) 2008-03-26
NO320099B1 (no) 2005-10-24
AU3154900A (en) 2000-09-14
KR20010102347A (ko) 2001-11-15
RU2236402C2 (ru) 2004-09-20
JO2254B1 (en) 2004-10-07
JP2002537382A (ja) 2002-11-05
YU59901A (sh) 2005-07-19
DE60015089T2 (de) 2006-02-16
EP1157005A1 (fr) 2001-11-28
SI1157005T1 (en) 2005-02-28
CN1341100A (zh) 2002-03-20
HK1044942B (zh) 2004-05-28
WO2000050401A1 (fr) 2000-08-31

Similar Documents

Publication Publication Date Title
DK1157005T3 (da) 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister
DK1035115T3 (da) 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
NO20013809L (no) Indolderivater og anvendelse derav som MCP-1 antagonister
DK1345920T3 (da) Hidtil ukendte sulfamider og anvendelse deraf som endothelinreceptorantagonister
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
NO20021689D0 (no) 5-rings heterosykliske derivater, fremstilling derav og anvendelse som medikamenter
NO20031952L (no) 3-aroylinderivater og deres anvendelse som CB2 reseptoragonister
NO20021719L (no) 6-posisjon substituerte indoliner, fremstilling og anvendelse derav som medikament
DK1345937T3 (da) Quinuclidincarbamatderivater og deres anvendelse som M3-antagonister
NO20043064L (no) 1-alkyl-1-azoniabisyklo [2.2.2] oktankarbamatderivater og anvendelse av disse som muskarine reseptorantagonister
NO20041008L (no) Karbazolderivater og anvendelse derav som NPY5 reseptor antagonister
DK1170288T3 (da) Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister
NO996115D0 (no) Azetidinylpropylpiperidin-derivater, intermediater og anvendelse som tachykinin-antagonister
NO20025640L (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptorantagonister
NO995482L (no) Ergolinderivater og deres anvendelse som somatostatinreseptorantagonister
DK1335906T3 (da) Pyrimidinderivater og anvendelse deraf som neuropeptid Y-receptorligander
NO20025762D0 (no) Bicykliske cykloheksylaminer og anvendelse derav som NMDA- reseptorantagonister
DK1216250T3 (da) Thienoisoxazolyl- og thienylpyrazolyl-phenoxy- substituerede propylderivater som D4-antagonister
DK1296961T3 (da) 1,4-diazepan-2,5-dionderivater og anvendelse deraf som NK-1-receptorantagonister
NO20004144D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse som takykinin reseptor antagonister
NO20014224D0 (no) 4-heterocyklysulfonamidyl-6-metoksy-5-(2-metoksy-fenoksy)-2- pyridyl-pyrimidinderivater, fremstilling derav og anvendelse somendotelin reseptor antagonister
NO992976D0 (no) Heterocykliske karboksylsyre-derivater, fremstilling og anvendelse derav som endothelinreseptor-antagonister
NO20043799L (no) 2-oksasolaminer og deres anvendelse som 5-HT2B reseptor antagonister
NO20021249L (no) Tienoisoksazolfenoksyusubstituerte etyl- og propylderivater anvendbare som D4antagonister